Low-dose acetylsalicylic acid inhibits the secretion of interleukin-6 from white adipose tissue.
Autor: | Ogston NC; Adipokines and Metabolism Research Group, University College London, London, UK., Karastergiou K, Hosseinzadeh-Attar MJ, Bhome R, Madani R, Stables M, Gilroy D, Flachs P, Hensler M, Kopecky J, Mohamed-Ali V |
---|---|
Jazyk: | angličtina |
Zdroj: | International journal of obesity (2005) [Int J Obes (Lond)] 2008 Dec; Vol. 32 (12), pp. 1807-15. Date of Electronic Publication: 2008 Nov 04. |
DOI: | 10.1038/ijo.2008.190 |
Abstrakt: | Background: Chronically elevated interleukin-6 (IL-6) is implicated in obesity-associated pathologies, where a proportion of this cytokine is derived from adipose tissue. Proinflammatory prostaglandins, which regulate this cytokine elsewhere, are also produced by this tissue. Objective: To investigate whether constitutively active cyclooxygenase (COX)/prostaglandin (PG) pathway in white adipose tissue (WAT) is responsible for basal IL-6 production. Design: The effect of acetylsalicylic acid (ASA), an inhibitor of COX, on IL-6 was assessed in human subjects and mice. COX, downstream PG synthase (PGS) activity and PG receptor signalling were determined in subcutaneous (SC), gonadal (GN) WAT and adipocytes. Methods and Results: In obese humans, low-dose ASA (150 mg day(-1) for 10 days) inhibited systemic IL-6 and reduced IL-6 release from SC WAT ex vivo (0.2 mM). Similarly, in mice, ASA (0.2 and 2.0 mg kg(-1)) suppressed SC WAT 6-keto-PGF(1alpha) (a stable metabolite of prostacyclin) and IL-6 release. Although both COX isoforms are comparably expressed, prostacyclin synthase expression is higher in GN WAT, with levels of activity correlating directly with IL-6. Both ASA (5 mM) and NS-398 (COX-2 selective inhibitor |
Databáze: | MEDLINE |
Externí odkaz: |